Reply

Markos Kalligeros; Eleftherios Mylonakis; Mazen Noureddin

doi:10.1016/j.cgh.2024.01.036

Reply

Markos Kalligeros, Eleftherios Mylonakis, Mazen Noureddin

Research output: Contribution to journal › Letter › peer-review

Abstract

We appreciate the interest of Fouad and coworkers in our study regarding the prevalence of steatotic liver disease (SLD) in the United States. 1 Our research is in line with the revised nomenclature to categorize SLD subtypes. In their recent letter to the editor, Fouad et al 2 express concerns about the newly adapted nomenclature, particularly in the context of mixed etiologies contributing to SLD. They suggest that the previously proposed nomenclature, specifically metabolic-associated fatty liver disease (MAFLD), might be superior in certain scenarios.

Original language	English (US)
Pages (from-to)	1752
Number of pages	1
Journal	Clinical Gastroenterology and Hepatology
Volume	22
Issue number	8
DOIs	https://doi.org/10.1016/j.cgh.2024.01.036
State	Published - Aug 2024

ASJC Scopus subject areas

Hepatology
Gastroenterology

Divisions

Gastroenterology and Hepatology
Infectious Disease

Access to Document

10.1016/j.cgh.2024.01.036

Cite this

@article{179101b561e8444c8db6b78b95f62a0d,

title = "Reply",

abstract = "We appreciate the interest of Fouad and coworkers in our study regarding the prevalence of steatotic liver disease (SLD) in the United States. 1 Our research is in line with the revised nomenclature to categorize SLD subtypes. In their recent letter to the editor, Fouad et al 2 express concerns about the newly adapted nomenclature, particularly in the context of mixed etiologies contributing to SLD. They suggest that the previously proposed nomenclature, specifically metabolic-associated fatty liver disease (MAFLD), might be superior in certain scenarios.",

author = "Markos Kalligeros and Eleftherios Mylonakis and Mazen Noureddin",

year = "2024",

month = aug,

doi = "10.1016/j.cgh.2024.01.036",

language = "English (US)",

volume = "22",

pages = "1752",

journal = "Clinical Gastroenterology and Hepatology",

issn = "1542-3565",

publisher = "W.B. Saunders",

number = "8",

}

TY - JOUR

T1 - Reply

AU - Kalligeros, Markos

AU - Mylonakis, Eleftherios

AU - Noureddin, Mazen

PY - 2024/8

Y1 - 2024/8

N2 - We appreciate the interest of Fouad and coworkers in our study regarding the prevalence of steatotic liver disease (SLD) in the United States. 1 Our research is in line with the revised nomenclature to categorize SLD subtypes. In their recent letter to the editor, Fouad et al 2 express concerns about the newly adapted nomenclature, particularly in the context of mixed etiologies contributing to SLD. They suggest that the previously proposed nomenclature, specifically metabolic-associated fatty liver disease (MAFLD), might be superior in certain scenarios.

AB - We appreciate the interest of Fouad and coworkers in our study regarding the prevalence of steatotic liver disease (SLD) in the United States. 1 Our research is in line with the revised nomenclature to categorize SLD subtypes. In their recent letter to the editor, Fouad et al 2 express concerns about the newly adapted nomenclature, particularly in the context of mixed etiologies contributing to SLD. They suggest that the previously proposed nomenclature, specifically metabolic-associated fatty liver disease (MAFLD), might be superior in certain scenarios.

UR - https://www.scopus.com/pages/publications/85188431227

UR - https://www.scopus.com/inward/citedby.url?scp=85188431227&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2024.01.036

DO - 10.1016/j.cgh.2024.01.036

M3 - Letter

C2 - 38346568

AN - SCOPUS:85188431227

SN - 1542-3565

VL - 22

SP - 1752

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

IS - 8

ER -

Reply

Abstract

ASJC Scopus subject areas

Divisions

Access to Document

Other files and links

Fingerprint

Cite this